CRISPR Therapeutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	401.07	223.52	939.94	1,185	948.81	459.81	242.91	318.67	156.66	1
Short-Term Investments	1,304	1,603	1,456	521.71	0	0	0	0	0	0
Cash & Cash Equivalents	1,705	1,827	2,396	1,707	948.81	459.81	242.91	318.67	156.66	1
Cash Growth	-6.66%	-23.75%	40.35%	79.93%	106.35%	89.29%	-23.77%	103.41%	15644.82%	-
Receivables	200	0	0.31	0.14	0.1	0.09	2.63	3.16	0.34	0
Other Current Assets	2.8	26.07	21.17	9.3	38.64	6.5	2.85	-1.64	-0.16	-0.03
Total Current Assets	1,908	1,853	2,418	1,717	987.55	466.4	248.39	320.19	156.84	0.97
Property, Plant & Equipment	305.94	320.56	312.04	93.03	72.83	18.5	18.86	21.03	1.33	0
Long-Term Investments	1.97	53.13	0	0	0	0	0	0	0	0
Goodwill and Intangibles	0.02	0.07	0.13	0.18	0.24	0.29	0.34	0.4	0.45	0.51
Other Long-Term Assets	13.57	16.28	22.2	18.14	6.14	3.83	3.76	3.35	0.8	0.05
Total Long-Term Assets	321.49	390.03	334.36	111.35	79.21	22.62	22.96	24.77	2.58	0.56
Total Assets	2,230	2,243	2,752	1,828	1,067	489.02	271.35	344.96	159.42	1.53
Accounts Payable	38.15	27.43	14.82	9.09	5.94	5.07	1.64	4.57	1.58	0.21
Deferred Revenue	18.12	12.32	13.33	14.12	12.74	57.88	56.93	77.65	75.09	0
Current Debt	15.63	15.84	12.16	11.36	8.49	0	0	0	0	0
Other Current Liabilities	36.9	65.51	79.58	59.69	29.94	-35.21	-44.06	-60.22	-66.52	1.94
Total Current Liabilities	108.79	121.11	119.88	94.26	57.11	27.75	14.51	22	10.16	2.15
Long-Term Debt	223.01	228.18	212.87	50.07	44.05	0	0	0	38.34	0
Other Long-Term Liabilities	14.97	18.29	19.66	19.41	26.17	69.08	69	90.12	75.54	0.09
Total Long-Term Liabilities	237.98	246.47	232.53	69.47	70.22	69.08	69	90.12	113.87	0.09
Total Liabilities	346.77	367.58	352.42	163.73	127.33	96.82	83.51	112.12	124.03	2.23
Total Debt	238.63	244.02	225.03	61.43	52.54	0	0	0	38.34	0
Debt Growth	-2.21%	8.44%	266.33%	16.92%	-	-	-	-	-	-
Retained Earnings	-999.7	-846.09	-195.92	-573.58	-224.71	-291.57	-125.44	-57.08	-33.91	-8.4
Comprehensive Income	1.91	-15.65	-5.07	-0.08	0.01	-0.01	0.01	-0.03	-0.01	-0
Shareholders' Equity	1,883	1,875	2,399	1,664	939.43	392.2	187.83	232.85	-29.1	-7.12
Net Cash / Debt	1,467	1,583	2,171	1,646	896.27	459.81	242.91	318.67	118.33	1
Net Cash / Debt Growth	-7.35%	-27.09%	31.92%	83.62%	94.92%	89.29%	-23.77%	169.32%	11791.96%	-
Net Cash Per Share	18.51	20.36	27.00	24.95	15.74	9.59	6.06	26.00	23.49	0.28
Working Capital	1,799	1,732	2,298	1,622	930.44	438.65	233.87	298.19	146.69	-1.18
Book Value Per Share	23.77	24.12	31.59	25.23	17.27	8.18	4.69	19.00	-5.78	-2.00

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).